• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Tackling insulin resistance may reduce recurrence after stroke
Giving pioglitazone to stroke survivors with insulin resistance but no overt diabetes reduces their risk of having a recurrent vascular event, shows the randomised Insulin Resistance Intervention after Stroke trial.
Source: MedWire News - February 19, 2016 Category: Consumer Health News Tags: Stroke Source Type: news

Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: World Pharma News - February 18, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes Drug May Help Prevent Second Stroke
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news

Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news

Diabetes drug may prevent heart attack, recurring stroke
Stephen FellerNEW HAVEN, Conn., Feb. 17 (UPI) -- The diabetes drug Actos was shown to lower the risk of recurring stroke and heart attack in a large clinical trial of insulin-resistant stroke patients.
Source: Health News - UPI.com - February 17, 2016 Category: Consumer Health News Source Type: news

Diabetes Drug May Help Prevent Second Stroke
Actos reduced risk by 24 percent in people with insulin resistance, research showed Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Stroke
Source: MedlinePlus Health News - February 17, 2016 Category: Consumer Health News Source Type: news

Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: U.S. News - Health - February 17, 2016 Category: Consumer Health News Source Type: news

IRIS: Diabetes Drug Reduces Recurrent Stroke, MIIRIS: Diabetes Drug Reduces Recurrent Stroke, MI
A randomized trial shows that in patients with insulin resistance but no diabetes and a history of recent stroke or TIA, pioglitazone reduced recurrent stroke and myocardial infarction vs placebo. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - February 17, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Diabetes Drug May Help Prevent Second Stroke: Study
WEDNESDAY, Feb. 17, 2016 -- The diabetes drug Actos (pioglitazone) appears to protect people who've already had a stroke from suffering a second stroke, a new study finds. Along with standard treatment after a stroke -- including blood thinners, and...
Source: Drugs.com - Daily MedNews - February 17, 2016 Category: Journals (General) Source Type: news

Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - February 17, 2016 Category: Neurology Source Type: news

Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - January 8, 2016 Category: Endocrinology Authors: E. Erdmann, S. Harding, H. Lam, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

10‐Year Observational Follow‐Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution due to limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - November 23, 2015 Category: Endocrinology Authors: Erland Erdmann, Sarah Harding, Hung Lam, Alfonso Perez Tags: ORIGINAL ARTICLE Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
CONCLUSIONS: PPAR-γ agonists appear to reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and improve insulin sensitivity and the stabilisation of carotid plaques. There is evidence of limited quality that they are well tolerated. However, the conclusions should be interpreted with caution considering the small number and the quality of the included studies. In future, well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular events in p...
Source: Cochrane Database of Systematic Reviews - October 29, 2015 Category: Journals (General) Authors: Liu J, Wang LN Tags: Cochrane Database Syst Rev Source Type: research

Pages: 1  2  3  4  5  6  7  8